Related Experiment Video

Updated: May 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer

Sarah Waliany1, Jessica J Lin1, Justin F Gainor1

  • 1Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

Trends in Cancer
|January 31, 2025
PubMed

Insights

Targeted therapies have transformed metastatic lung cancer treatment, especially for EGFR, ALK, and ROS1-driven cancers. Future strategies may involve combination therapies for less responsive oncogenic drivers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic lung cancers driven by specific oncogenes (e.g., EGFR, ALK, ROS1) have seen revolutionary treatment advances.
  • Next-generation targeted therapies offer improved potency, selectivity, and brain penetration, shifting treatment paradigms towards first-line use.

Purpose of the Study:

  • To review lessons learned from targeted therapy development in oncogene-addicted lung cancers.
  • To discuss the role of tumor biology and resistance mechanisms in guiding drug development.
  • To explore future strategies for challenging oncogenic drivers.

Main Methods:

  • Review of clinical practice evolution in targeted lung cancer therapy.
  • Analysis of translational insights into oncogene-driven lung cancer.
  • Examination of mechanisms of therapeutic resistance.

Main Results:

  • Successive generations of targeted therapies have enhanced treatment outcomes for specific lung cancer subsets.
  • First-line use of next-generation drugs is becoming standard for certain oncogene-addicted lung cancers.
  • Understanding tumor biology and resistance is crucial for effective drug development.

Conclusions:

  • Targeted therapies have significantly improved outcomes for metastatic lung cancers with actionable oncogenic drivers.
  • Combination strategies are likely necessary for first-line treatment of lung cancers with drivers less sensitive to single agents.
  • Continued research into tumor biology and resistance mechanisms will drive future therapeutic advancements.
Keywords:
first-line therapyoff-target resistanceon-target resistance mutationsrationally designed combination therapiestargeted therapies

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K